Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.66 |
| ▸ | MTOR | P42345 | 10/20 | 0.65 |
| ▸ | ATR | Q13535 | 5/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.51 |
| ▸ | ATRIP | Q8WXE1 | 4/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8213703 | 0.93 | PIK3CA (0.67) | PIK3CAPIK3CDMTORATRCHEK1 | |
| SCHEMBL4529862 | 0.88 | PIK3CA (0.72) | PIK3CAPIK3CDMTORATRCHEK1 | |
| SCHEMBL4526678 | 0.87 | MTOR (0.74) | PIK3CAPIK3CDMTORATRCHEK1 | |
| SCHEMBL739897 | 0.86 | PIK3CA (0.72) | PIK3CAPIK3CDMTORATRCHEK1 | |
| SCHEMBL3051750 | 0.86 | PIK3CA (0.77) | PIK3CAPIK3CDMTORATRCHEK1 | |
| SCHEMBL13606537 | 0.85 | MTOR (0.74) | PIK3CAPIK3CDMTORATR | |
| SCHEMBL3050571 | 0.83 | PIK3CA (0.81) | PIK3CAPIK3CDMTORATRCHEK1 | |
| SCHEMBL738142 | 0.83 | PIK3CA (0.81) | PIK3CAPIK3CDMTORATRCHEK1 | |
| SCHEMBL13257213 | 0.82 | PIK3CA (0.80) | PIK3CAPIK3CDMTORATRCHEK1 | |
| SCHEMBL4538321 | 0.81 | MTOR (0.68) | PIK3CAPIK3CDMTORATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325957-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090325957-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090325957-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325957-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | TYMP, PIK3CA, TYMS | PIK3CA 2/4885PIK3CD 5/4885MTOR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.